{"data":[{"accessionNo":"0000902664-26-003506","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4600000,"percentOfClass":5.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000902664-26-003506","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":4600000,"percentOfClass":5.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000919574-26-005533","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Montanova Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":3549539,"percentOfClass":4.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000919574-26-005533","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Aaron Cowen","reportingCik":null,"personType":"HC,IN","sharesOwned":3549539,"percentOfClass":4.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000919574-26-005533","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Averill Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3215486,"percentOfClass":3.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000080255-26-000442","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001826457","issuerName":"MONTE ROSA THERAPEUTICS INC","ticker":"GLUE","cusip":"61225M102","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":8861282,"percentOfClass":10.5,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"New Enterprise Associates 17, L.P.","reportingCik":"0001768564","personType":"PN","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Scott D. Sandell","reportingCik":"0001237289","personType":"IN","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Mohamad H. Makhzoumi","reportingCik":"0001630226","personType":"IN","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Anthony A. Florence, Jr.","reportingCik":"0001559827","personType":"IN","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"NEA 17 GP, LLC","reportingCik":"0001796821","personType":"OO","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"NEA Partners 17, L.P.","reportingCik":"0001796820","personType":"PN","sharesOwned":6692298,"percentOfClass":7.9,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Ali Behbahani","reportingCik":"0001613867","personType":"IN","sharesOwned":135432,"percentOfClass":0.2,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Rick Yang","reportingCik":"0001851328","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Paul Walker","reportingCik":"0001553150","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Edward T. Mathers","reportingCik":"0001328625","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Carmen Chang","reportingCik":"0001746342","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000558","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-01","reportingPerson":"Forest Baskett","reportingCik":"0001277631","personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-062588","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Baker Bros. Advisors (GP) LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":8876346,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-062588","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Felix J. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":8876346,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-062588","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Baker Bros. Advisors LP","reportingCik":null,"personType":"IA,PN","sharesOwned":8876346,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-062588","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Julian C. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":8876346,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":5085886,"percentOfClass":6.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":5085886,"percentOfClass":6.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":5085886,"percentOfClass":6.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":4703553,"percentOfClass":5.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-226862","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":4622151,"percentOfClass":5.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2716569,"percentOfClass":3.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":2716569,"percentOfClass":3.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-226862","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":2311076,"percentOfClass":2.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-226862","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover Fund III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2311075,"percentOfClass":2.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-226862","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":2311075,"percentOfClass":2.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-226862","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2311076,"percentOfClass":2.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1986984,"percentOfClass":2.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1986984,"percentOfClass":2.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":306361,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-001394","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":306361,"percentOfClass":0.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Nan Li","reportingCik":null,"personType":"IN","sharesOwned":6513765,"percentOfClass":8.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Management, L.P.","reportingCik":null,"personType":"IA","sharesOwned":6513765,"percentOfClass":8.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Management GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":6513765,"percentOfClass":8.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Adam Goulburn","reportingCik":null,"personType":"IN","sharesOwned":6513765,"percentOfClass":8.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Zavain Dar","reportingCik":null,"personType":"IN","sharesOwned":6513765,"percentOfClass":8.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Capital I GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":5663265,"percentOfClass":7.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Capital I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5663265,"percentOfClass":7.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Capital II GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":850500,"percentOfClass":1.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-170903","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dimension Capital II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":850500,"percentOfClass":1.1,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Ali Behbahani","reportingCik":"0001613867","personType":"IN","sharesOwned":7797030,"percentOfClass":9.7,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Rick Yang","reportingCik":"0001851328","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Paul Walker","reportingCik":"0001553150","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Scott D. Sandell","reportingCik":"0001237289","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Edward T. Mathers","reportingCik":"0001328625","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"New Enterprise Associates 17, L.P.","reportingCik":"0001768564","personType":"PN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"NEA Partners 17, L.P.","reportingCik":"0001796820","personType":"PN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"NEA 17 GP, LLC","reportingCik":"0001796821","personType":"OO","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Carmen Chang","reportingCik":"0001746342","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Forest Baskett","reportingCik":"0001277631","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Anthony A. Florence, Jr.","reportingCik":"0001559827","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001072613-26-000294","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":"61225M102","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-17","reportingPerson":"Mohamad H. Makhzoumi","reportingCik":"0001630226","personType":"IN","sharesOwned":7692298,"percentOfClass":9.6,"filedAt":"2026-03-19","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-016412","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Baker Bros. Advisors LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4345736,"percentOfClass":6.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-016412","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Baker Bros. Advisors (GP) LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":4345736,"percentOfClass":6.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-016412","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Julian C. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":4345736,"percentOfClass":6.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001104659-26-016412","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Felix J. Baker","reportingCik":null,"personType":"HC,IN","sharesOwned":4345736,"percentOfClass":6.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":3835886,"percentOfClass":5.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":3835886,"percentOfClass":5.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":3835886,"percentOfClass":5.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":3547264,"percentOfClass":5.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":2050405,"percentOfClass":3.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2050405,"percentOfClass":3.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1496859,"percentOfClass":2.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1496859,"percentOfClass":2.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":232097,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000921895-26-000461","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":232097,"percentOfClass":0.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dimension Capital I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dimension Management GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dimension Capital I GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dimension Management, L.P.","reportingCik":null,"personType":"IA","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Nan Li","reportingCik":null,"personType":"IN","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Zavain Dar","reportingCik":null,"personType":"IN","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Adam Goulburn","reportingCik":null,"personType":"IN","sharesOwned":5663265,"percentOfClass":8.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Ventures VI GP-GP, LLC","reportingCik":"0001777652","personType":"OO","sharesOwned":2236708,"percentOfClass":3.4,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Venture Capital VI, L.P.","reportingCik":"0001687880","personType":"PN","sharesOwned":2236708,"percentOfClass":3.4,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Ventures VI GP, L.P.","reportingCik":"0001777654","personType":"PN","sharesOwned":2236708,"percentOfClass":3.4,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Vantage I GP-GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":1013361,"percentOfClass":1.6,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Vantage I GP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1013361,"percentOfClass":1.6,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-26-008951","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-01-07","reportingPerson":"Versant Vantage I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1013361,"percentOfClass":1.6,"filedAt":"2026-01-09","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000080255-25-000838","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001826457","issuerName":"MONTE ROSA THERAPEUTICS INC","ticker":"GLUE","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":4637060,"percentOfClass":7.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000902664-25-004946","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Behzad Aghazadeh","reportingCik":null,"personType":"HC,IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000902664-25-004946","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Avoro Capital Advisors LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Ventures VI GP-GP, LLC","reportingCik":"0001777652","personType":"OO","sharesOwned":3334669,"percentOfClass":5.1,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Ventures VI GP, L.P.","reportingCik":"0001777654","personType":"PN","sharesOwned":3334669,"percentOfClass":5.1,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Venture Capital VI, L.P.","reportingCik":"0001687880","personType":"PN","sharesOwned":3334669,"percentOfClass":5.1,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Vantage I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1573453,"percentOfClass":2.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Vantage I GP-GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":1573453,"percentOfClass":2.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-277603","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-10","reportingPerson":"Versant Vantage I GP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1573453,"percentOfClass":2.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0000102909-25-000255","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics Inc","ticker":"GLUE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":2988953,"percentOfClass":4.83,"filedAt":"2025-10-31","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-242555","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-10","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":4427705,"percentOfClass":7.2,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-242555","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-10","reportingPerson":"TCG Crossover Fund III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2213852,"percentOfClass":3.6,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-242555","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-10","reportingPerson":"TCG Crossover GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":2213852,"percentOfClass":3.6,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-242555","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-10","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2213853,"percentOfClass":3.6,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001193125-25-242555","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-10","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":2213853,"percentOfClass":3.6,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Dimension Capital I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Dimension Management GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Dimension Capital I GP, LLC","reportingCik":null,"personType":"CO","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Dimension Management, L.P.","reportingCik":null,"personType":"IA","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Nan Li","reportingCik":null,"personType":"IN","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Zavain Dar","reportingCik":null,"personType":"IN","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"},{"accessionNo":"0001012975-25-000601","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001826457","issuerName":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2024-05-16","reportingPerson":"Adam Goulburn","reportingCik":null,"personType":"IN","sharesOwned":4757563,"percentOfClass":7.7,"filedAt":"2025-10-03","canonicalUrl":"https://xoomar.com/markets/stocks/glue"}],"updatedAt":"2026-11-05T08:30:11.850Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/glue","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}